Mylan to launch Humira biosim in Europe

Sep 21, 2018

Mylan and Fujifilm Kyowa Kirin Biologics announced that the European Commission has granted marketing authorization for Hulio, a biosimilar to AbbVie's Humira (adalimumab), for all indications.

This is the fifth biosimilar to the top-selling Humira approved by the European Commission. Boehringer Ingelheim and Novartis' Sandoz also have EU-approved biosimilars -- neither of which have been launched yet.

The EC approval of Hulio applies to all 28 EU member countries and European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. Mylan plans to launch Hulio across various markets in Europe on or after Oct. 16.

Read the press release

Don't miss your Daily Dose! Subscribe to the daily eNewsletter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments